Welcome to PCI Biotech

PCI Biotech® has developed a unique and patented photochemical drug delivery technology for use in cancer therapy and other diseases.

PCI Biotech® collaborates closely with The Norwegian Radium Hospital in Oslo, Norway and receives substantial funding on several projects from both the Norwegian Research Council and the EU.  The company has an extensive international collaboration network with recognised drug delivery expert groups.

PCI (PhotoChemical Internalisation) is a technology for light-directed drug delivery by triggered endosomal release and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells.

The PCI technology has potential to improve the effect both of existing drugs and of emerging treatments such as gene therapy and other therapies based on nanotechnology or on biotechnological principles. The company’s objective is to prove the clinical usefulness of the technology with different drugs and subsequently license out the technology to partners for further development and marketing with their drugs. Revenues will be generated at the time of partnering and onwards from up-front payments, milestone payments and royalties from licensees.

Please contact us, for more information.